A Clinical Trial of Renin Profiling in Selection of Initial Antihypertensive Drug
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 185
- Locations
- 5
- Primary Endpoint
- Percent of patients with BP <140/90 mmHg and on monotherapy at the 5th visit.
Study Overview
Brief Summary
The purpose of this research study is to determine whether a simple blood test measuring a hormone called renin can better determine which first drug would be most effective in controlling blood pressure, in comparison with the more traditional approach recommended by JNC7 (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure).
Detailed Description
Hypothesis: That antihypertensive drug selection guided by activity of the renin angiotensin system will be superior to the strategy advocated in JNC 7 in achieving blood pressure control on monotherapy.
Background: the National Heart, Lung, and Blood Institute, through the Joint National Committee on the Detection, Treatment and Control of Hypertension (JNC 7) has recommended that most hypertensive patients begin therapy with a diuretic and sequentially add other classes of drugs until blood pressure is controlled. This approach appears to assume homogeneity in the mechanism by which BP is controlled in different patients. When this standardized strategy has been rigidly applied in Clinical Trials, a majority of patients generally require 2 or more agents to achieve blood pressure control.
The pioneering work of Laragh, Sealey and their colleagues, widely confirmed by others, suggests instead that heterogeneity, in fact, characterizes patterns of blood pressure control in populations. This heterogeneity can be exposed through assessment of the activity of the renin angiotensin system (RAS). Specifically, volume and vasoconstriction determine blood pressure control. Patients in whom volume predominates have suppressed RAS, and, conversely, those in whom vasoconstriction predominates will have an activated RAS. This can be simply and accurately determined by estimation of plasma renin activity (PRA).
It has been demonstrated that volume and vasoconstriction dependent hypertensive patients respond best to different drugs. By exploitation of the RAS it is possible to provide rational therapy to each patients according to the mechanism by which blood pressure is controlled. The result is that appropriate therapy can be both more effective and more efficient. A specific system the Laragh Method has been designed to translate this physiologically based paradigm into a practical scheme or patient management.
The purpose of this trial is to determine whether the Laragh Method will lead to better and more efficient blood pressure control in a general population of hypertensive patients than does the existing treatment strategy. The measure by which this hypothesis will be tested is percentage of hypertensive patients achieving blood pressure control on monotherapy.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 40 Years to 85 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Males and females, 40 to 85 years of age
- •Sustained systolic blood pressure between 140-180 mm Hg
- •Free of antihypertensive therapy at randomization for at least 4 weeks
- •Exclusion criteria:
- •Ages <40, or >85 years
- •Systolic blood pressure >180 mm Hg
- •Blood pressure >180/105 mm Hg during the washout period
- •Require antihypertensive agents for non-blood pressure indications
- •Taking clonidine
- •On a beta-blocker drug and have known or suspected coronary artery disease
- •Documented history of a heart attack, new onset of chest pain, or a coronary revascularization procedure within the past year, congestive heart failure
- •Serious intercurrent illness
- •An active ulcer
- •Have certain abnormal laboratory tests (elevated serum creatinine >1.5 mg/dl, transaminase > 2 times upper limit of normal or active liver disease),
- •Hypersensitivity, allergy or have an intolerance to angiotensin II receptor blockers (olmesartan), hydrochlorothiazide or amlodipine
- •Mentally or legally unable to participate
- •Have or are currently abusing alcohol, have abused drugs within the past 2 years
- •Have been in another drug study in the past month.
Exclusion Criteria
- Not provided
Arms & Interventions
HCTZ , ARB
Patients randomized to the Experimental Arm have initial drug choice determined by Plasma Renin Activity level. Low renin subjects are assigned to the diuretic hydrochlorothothiazide. Those with PRA >.65 ng/hr are assigned to the angiotensin receptor blocker, olmesartan.
Intervention: olmesartan, hydrochlorothiazide, amlodipine (Drug)
HCTZ , ARB
Patients randomized to the Experimental Arm have initial drug choice determined by Plasma Renin Activity level. Low renin subjects are assigned to the diuretic hydrochlorothothiazide. Those with PRA >.65 ng/hr are assigned to the angiotensin receptor blocker, olmesartan.
Intervention: hydrochlorothiazide (HCTZ) or olmesartan (Drug)
Conventional antihypertensive therapy
All patients randomized to Active Comparator Arm received hydrochlorothiazide 25 mg, which is increased to 50 mg at 3-4 weeks. At 6 weeks, olmesartan may be added if BP > 140 mmHg
Intervention: olmesartan, hydrochlorothiazide, amlodipine (Drug)
Conventional antihypertensive therapy
All patients randomized to Active Comparator Arm received hydrochlorothiazide 25 mg, which is increased to 50 mg at 3-4 weeks. At 6 weeks, olmesartan may be added if BP > 140 mmHg
Intervention: hydrochlorothiazide (HCTZ) or olmesartan (Drug)
Outcomes
Primary Outcomes
Percent of patients with BP <140/90 mmHg and on monotherapy at the 5th visit.
Time Frame: 3-4 months
Secondary Outcomes
- Will include change in blood pressure, percent of patients with blood pressure <140/mmHg, total number of classes of antihypertensive agents taken, adverse events and discontinuation of therapy.(3-4 months)
- In addition, we will be able to determine the reproducibility of PRA determination in this clinical setting. Finally, it will be possible to demonstrate the value of "in-treatment" PRA as a guide to treatment modification.(3-4 months)
Investigators
Michael H. Alderman
Professor of Epidemiology and Population Health
The Louis & Rachel Rudin Foundation